Temporal changes in survival in men with de novo metastatic prostate cancer: nationwide population-based study

References

• Annual report. 2018. from The National Prostate Cancer Register. In Swedish. [cited 2019 Sep 09]. Available from: http://npcr.se/wp-content/uploads/2019/09/20190905_npcr_nationell_rapport_2018.pdf.
   Google Scholar
• Stattin P, Sandin F, Loeb S, et al. Public online reporting from a nationwide population‐based clinical prostate cancer register. BJU Int. 2018;122(1):8–10.
   PubMed Web of Science ®Google Scholar
• Jonsson H, Holmstrom B, Duffy SW, et al. Uptake of prostate-specific antigen testing for early prostate cancer detection in Sweden. Int J Cancer. 2011;129(8):1881–1888.
   PubMed Web of Science ®Google Scholar
• Ohmann EL, Loeb S, Robinson D, et al. Nationwide, population-based study of prostate cancer stage migration between and within clinical risk categories. Scand J Urol. 2014;48(5):426–435.
   PubMed Web of Science ®Google Scholar
• Bray F, Lortet-Tieulent J, Ferlay J, et al. Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer. 2010;46(17):3040–3052.
   PubMed Web of Science ®Google Scholar
• Cazzaniga W, Garmo H, Robinson D, et al. Mortality after radical prostatectomy in a matched contemporary cohort in Sweden compared to the Scandinavian Prostate Cancer Group 4 (SPCG‐4) study. BJU Int. 2018;123: 421–428.
   PubMed Web of Science ®Google Scholar
• Gravis G, Boher JM, Joly F, et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol. 2016;70(2):256–262.
   PubMed Web of Science ®Google Scholar
• Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–433.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, De Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138–148.
   PubMed Web of Science ®Google Scholar
• National guidelines for prostate cancer. In Swedish. [citedAug 20 2019]. Available from: https://www.cancercentrum.se/globalassets/cancerdiagnoser/prostatacancer/vardprogram/nationellt-vardprogram-prostatacancer.pdf.
   Google Scholar
• Lissbrant IF, Garmo H, Widmark A, et al. Population-based study on use of chemotherapy in men with castration resistant prostate cancer. Acta Oncol. 2013;52(8):1593–1601.
   PubMed Web of Science ®Google Scholar
• RATTEN - Interactive On Line Report from NPCR [cited 2019 Aug 20]. Available from: https://statistik.incanet.se/npcr/.
   Google Scholar
• Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40:244–252.
   PubMed Web of Science ®Google Scholar
• Van Hemelrijck M, Wigertz A, Sandin F, et al. Cohort Profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. Int J Epidemiol. 2013;42(4):956.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Makarov DV, Loeb S, Ulmert D, et al. Prostate cancer imaging trends after a nationwide effort to discourage inappropriate prostate cancer imaging. J Natl Cancer Inst. 2013;105(17):1306–1313.
   PubMedGoogle Scholar
• Cox DR. Regression models and life-tables. J Roy Stat Soc B (Methodological). 1972;34(2):187–220.
   Web of Science ®Google Scholar
• van Buuren S. Flexible imputation of missing data. Boca Raton (FL): CRC Press; 2012.
   Google Scholar
• Siddique J, Harel O, Crespi CM, et al. Binary variable multiple-model multiple imputation to address missing data mechanism uncertainty: application to a smoking cessation trial. Stat Med. 2014;33(17):3013–3028.
   PubMed Web of Science ®Google Scholar
• Tomic K, Westerberg M, Robinson D, et al. Proportion and characteristics of men with unknown risk category in the National Prostate Cancer Register of Sweden. Acta Oncol. 2016;55(12):1461–1466.
   PubMed Web of Science ®Google Scholar
• Tomic K, Berglund A, Robinson D, et al. Capture rate and representativity of The National Prostate Cancer Register of Sweden. Acta Oncol. 2015;54(2):158.
   PubMed Web of Science ®Google Scholar
• Tomic K, Sandin F, Wigertz A, et al. Evaluation of data quality in the National Prostate Cancer Register of Sweden (Reprinted). Eur J Cancer. 2015;51(9):1130–1130.
   Web of Science ®Google Scholar
• Ingelsson E, Ärnlöv J, Sundström J, et al. The validity of a diagnosis of heart failure in a hospital discharge register. Eur J Heart Fail. 2005;7(5):787–791.
   PubMed Web of Science ®Google Scholar
• Helgstrand JT, Røder MA, Klemann N, et al. Trends in incidence and 5‐year mortality in men with newly diagnosed, metastatic prostate cancer—a population‐based analysis of 2 national cohorts. Cancer. 2018;124(14):2931.
   PubMed Web of Science ®Google Scholar
• Bandini M, Pompe RS, Marchioni M, et al. Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study. Int Urol Nephrol. 2018;50(1):71–78.
   PubMed Web of Science ®Google Scholar
• James ND, Spears MR, Clarke NW, et al. Survival with newly diagnosed metastatic prostate cancer in the “Docetaxel Era”': data from 917 patients in the control arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol. 2015;67(6):1028–1038.
   PubMed Web of Science ®Google Scholar
• James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–1177.
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–746.
   PubMed Web of Science ®Google Scholar